Recommendation of the President – Attentin (dextroamphetamine)

On 31 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 5/2025 on the appropriateness of granting approval for reimbursement of the medicinal product Attentin (dextroamphetamine) for the indication: attention deficit hyperactivity disorder (ADHD)

Publication in Public Information Bulletin (BIP) >>